capAI secures exclusive Ageotype licence with £2 million purchase option

capAI has taken its first concrete step into its capMedical vertical by signing a licence and option agreement with R42 Group for Ageotype, an artificial intelligence-powered longevity and preventative health platform.

The agreement gives capAI an exclusive worldwide licence to develop and commercialise Ageotype for 12 months. It also gives the company the option to acquire the platform's intellectual property for £2 million.

For investors, this is a strategically significant announcement rather than evidence of near-term financial performance. Ageotype is live in beta and has reached minimum viable product status, but revenue, customer numbers, launch targets and development costs have not been disclosed.

The Ageotype deal at a glance

Key term	Detail
Licence scope	Exclusive and worldwide
Licence period	12 months
Expected expiry	22 July 2027
IP purchase option	£2 million
R42's future entitlement	20% of net proceeds from IP monetisation after option exercise
Current development stage	Minimum viable product with live beta
capAI vertical	capMedical

The licence period gives capAI a defined window in which to develop the platform, test its commercial potential and decide whether acquiring the underlying intellectual property makes sense.

No upfront licence fee has been disclosed. The announcement also does not provide financial forecasts, revenue expectations or a budget for bringing Ageotype towards commercial launch.

What does Ageotype actually do?

Ageotype is designed to bring several types of health information into one AI-powered dashboard. Its data sources can include whole-body and brain magnetic resonance imaging, blood-based metabolomics, multi-cancer early detection blood testing and gut microbiome analysis.

Metabolomics means the study of small molecules produced by the body's biological processes. In simple terms, the platform is trying to combine different health signals into a more joined-up picture.

Users receive a personalised Ageotype classification showing which biological system may be ageing fastest relative to their chronological age. The systems covered are:

• Brain
• Heart
• Metabolic
• Immune
• Microbiome

The platform then provides plain-language, AI-generated insights and allows changes to be tracked over time.

Ageotype is intended to operate through a tiered commercial model. This ranges from a free entry-level portal to a premium annual programme incorporating diagnostics, physician consultation and a personalised longevity roadmap.

That structure could give capAI several ways to attract and monetise users. However, pricing, conversion assumptions and the economics of the premium service are not disclosed.

Ageotype does not provide medical advice, diagnosis or treatment, according to the announcement.

Why the agreement matters for capAI

The most important point is that Ageotype becomes capAI's first platform within capMedical, which was incorporated in October 2025.

Until now, the company had been assessing opportunities in medicine and longevity. This agreement moves the strategy from evaluation into an identifiable platform with a live beta product.

It also completes the licensing discussions first mentioned by capAI on 10 February 2026. That provides some evidence that the strategic alliance with R42 can produce signed transactions rather than remaining a pipeline of possibilities.

The platform is not starting from scratch. Minimum viable product status means that a basic functional version has already been built, while a live beta and demonstration profile are available to prospective users.

That could shorten the initial development journey. Even so, moving from beta testing to a scalable commercial service is a separate challenge. capAI still needs to demonstrate that Ageotype can attract paying customers, support medical and data-intensive workflows, and operate with viable economics.

The £2 million option needs careful reading

capAI has the discretion to acquire the Ageotype intellectual property for £2 million during the agreement period.

If the option is exercised, the consideration would be paid through newly issued ordinary shares and/or unsecured convertible loan notes. Convertible loan notes are debt instruments that may later be converted into shares.

The precise mix would depend partly on regulatory constraints, including the UK Takeover Code and the company's available prospectus headroom.

Issuing shares could dilute existing shareholders by increasing the number of shares in circulation. Convertible notes could also lead to future dilution if converted. The number of shares or terms of any loan notes have not been disclosed because the option has not yet been exercised.

R42 would additionally receive 20% of net proceeds from any future monetisation of the underlying intellectual property after option exercise. This means capAI would not retain the full economic benefit of a later sale or other monetisation event.

The agreement therefore gives capAI flexibility, but ownership would come with a material consideration and an ongoing economic entitlement for R42.

Related-party governance is a key issue

R42 was founded and is led by Professor Ronjon Nag, who is also capAI's executive chairman. The licence and option agreement is therefore a material related-party transaction.

Professor Nag recused himself from the board's deliberations and did not vote on the relevant resolutions. The decision was considered by independent directors Jack Allardyce, Sarah Jane Davy and Marcus Yeoman.

Those directors concluded that the terms were fair and reasonable for capAI and shareholders who are not related parties.

That process is important, although investors may still want to scrutinise transactions between capAI and R42 carefully. The announcement says most of the company's wider pipeline opportunities involve existing R42 portfolio companies, so related-party governance may remain relevant beyond Ageotype.

If capAI exercises the £2 million option, the transfer of the intellectual property and issue of shares or convertible loan notes would constitute a substantial property transaction under the Companies Act 2006. The company may proactively seek shareholder approval at a forthcoming general meeting.

The positives and the unanswered questions

The positive case is fairly clear. capAI has secured worldwide exclusivity over a working beta platform in a potentially large field. Ageotype combines several forms of health data, has a proposed tiered commercial model and gives capMedical a tangible starting point.

The announcement cites a global healthcare AI market valued at approximately US$39 billion in 2025 and projected to reach approximately US$1,033 billion by 2034, representing a compound annual growth rate of 44%. These are third-party market estimates cited by capAI, not company forecasts.

The main weakness is that commercial evidence remains limited. The announcement does not disclose:

• Ageotype revenue or customer numbers
• The number of beta users
• Commercial launch timing
• Development and marketing costs
• Regulatory requirements
• Pricing for paid tiers
• Expected margins or cash generation
• Funding arrangements for future development

There is also no certainty that capAI will exercise the purchase option. The 12-month licence creates a useful evaluation period, but also a deadline by which the company must make progress and decide whether the £2 million acquisition is justified.

What investors should watch next

The next meaningful updates should concern commercial launch plans, user adoption, partnerships and the development of business-to-business deployment opportunities.

Investors should also watch for any decision to exercise the option, the proposed form of consideration and whether shareholder approval is sought. Details on pricing, costs and early revenue would make it easier to judge Ageotype's economic potential.

For now, the agreement gives capAI a credible first asset for capMedical, but Ageotype remains a beta-stage opportunity. The strategic direction is clearer after this announcement. The commercial outcome is not.